[
  {
    "ts": "2026-01-16T10:52:00+00:00",
    "headline": "This Biotech Stock Is Up 100% This Year. Why It’s Soaring Again Today.",
    "summary": "ImmunityBio  stock is on a tear in 2026 and it looks like the biotech company’s stellar rally will keep going.  The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday.  Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.",
    "url": "https://www.barrons.com/articles/biotech-stock-immunitybio-cancer-drug-84f69281?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0175b06a-64b6-30aa-9f2c-e5a490c20c5a",
      "content": {
        "id": "0175b06a-64b6-30aa-9f2c-e5a490c20c5a",
        "contentType": "STORY",
        "title": "This Biotech Stock Is Up 100% This Year. Why It’s Soaring Again Today.",
        "description": "",
        "summary": "ImmunityBio  stock is on a tear in 2026 and it looks like the biotech company’s stellar rally will keep going.  The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday.  Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.",
        "pubDate": "2026-01-16T10:52:00Z",
        "displayTime": "2026-01-16T10:52:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0175b06a-64b6-30aa-9f2c-e5a490c20c5a/this-biotech-stock-is-up-100-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/415d32e72b2ef73c5fc85137488253a6",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nDMC3baXUtIHz_zTuDAnbQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/415d32e72b2ef73c5fc85137488253a6.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a4u6x7w5SgMGzOPHJ4jTmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/415d32e72b2ef73c5fc85137488253a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stock-immunitybio-cancer-drug-84f69281?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBRX"
            },
            {
              "symbol": "FDS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]